IMCIVREE™ (Setmelanotide)

May 29, 2026 — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced that seven presentations (including four late-breaking abstracts) were accepted for The Endocrine Society’s Annual Meeting (ENDO 2026), June 13–16, 2026, in Chicago. Key items include: updated results from an ongoing Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS), with new data to be shown from 17 of 18 patients after six months of therapy (the submitted abstract originally reflected 5 of 18 patients at six months); one-year weight reduction outcomes with bivamelagon (oral MC4R agonist) in acquired hypothalamic obesity (HO); and long-term setmelanotide efficacy in acquired HO including outcomes after 2.5 years (Phase 2 plus long-term extension). Additional Phase 3 setmelanotide data in acquired HO will address outcomes in participants with prior bariatric surgery and changes in weight category after one year. Rhythm will also present two late-breaking real-world evidence posters in Bardet-Biedl syndrome (RESTORE hyperphagia outcomes at 6 months; US weight and healthcare utilization outcomes with setmelanotide). Rhythm will host its inaugural “MOMENTUM” meeting on June 12 focused on MC4R pathway diseases.